Doximity (DOCS) delivered earnings and revenue surprises of -7.14% and +1.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Apenas manchetes de alto sinal — eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Doximity (DOCS) delivered earnings and revenue surprises of -7.14% and +1.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health (HIMS) delivered earnings and revenue surprises of -519.58% and -1.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
HIMS first-quarter 2026 results are likely to benefit from Labs and branded weight loss medications even as higher costs and GLP-1 scrutiny linger.
Enovis (ENOV) delivered earnings and revenue surprises of +8.54% and +3.68%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?